E. Anaissie

Infectious Diseases · 1999–2010

A researcher in the Science corpus: 12 papers; trusts 1 researcher and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Infectious Diseases — 45 citations into it; #364 of 589 by trust here, #145 by citations
• Epidemiology — 40 citations into it; #1,416 of 2,148 by trust here, #554 by citations
• Small Animals — 7 citations into it

Whom E. Anaissie trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. L. Romani

Who trusts E. Anaissie overall

1. M. Pfaller

Papers from E. Anaissie's perspective

Ordered by how strongly the researchers E. Anaissie trusts endorse each paper. Same corpus, a different order for every researcher.

1. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. (Clinical Infectious Diseases)
2. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (New England Journal of Medicine)
3. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. (New England Journal of Medicine)
4. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. (Clinical Infectious Diseases)
5. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (New England Journal of Medicine)
6. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (Clinical Microbiology Reviews)
7. Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality (Antimicrobial Agents and Chemotherapy)
8. Attributable mortality of nosocomial candidemia, revisited. (Clinical Infectious Diseases)
9. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. (Clinical Infectious Diseases)
10. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. (Clinical Infectious Diseases)

Their papers

• A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. (2006) — 935 citations
• Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. (2002) — 679 citations
• Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). (2010) — 1,457 citations
• Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. (2010) — 1,417 citations
• Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. (2009) — 796 citations
• Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009) — 976 citations
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008) — 2,622 citations
• Fusarium Infections in Immunocompromised Patients (2007) — 938 citations
• Thalidomide and hematopoietic-cell transplantation for multiple myeloma. (2006) — 742 citations
• Infections due to emerging and uncommon medically important fungal pathogens. (2004) — 608 citations
• Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (2002) — 951 citations
• Antitumor activity of thalidomide in refractory multiple myeloma. (1999)